DXCM — DexCom Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousLarge CapHigh Flyer

Annual income statement for DexCom, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	R2020 December 31st	R2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,927	2,449	2,910	3,622	4,033
Cost of Revenue
Gross Profit	1,305	1,709	1,897	2,306	2,492
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	1,627	2,183	2,519	3,025	3,433
Operating Profit	300	266	391	598	600
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	298	257	391	710	709
Provision for Income Taxes
Net Income After Taxes	550	217	341	542	576
Net Income Before Extraordinary Items
Net Income	550	217	341	542	576
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	550	217	341	542	576
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.37	0.61	0.831	1.3	1.51